ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy (previously referred to as ARS-1) for the emergency treatment of Type I allergic reactions, including anaphylaxis.
|Year||Equity||Revenue||EBITDA||Fin. Res.||Net Inc.||Net Mar.||ROE||Cash||Debt||N.D. / EBITDA||OCF||CAPEX||FCF||Free||Div.|
The values above are represented in USD and the scale is in millions—10.000 is the equivalent of 10 billions. L inside the table means Loss.